Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. TMB can be quantitated by a number of NGS-based sequencing technologies. Whole Exome Sequencing (WES) allows comprehensive measu...
Saved in:
Main Authors: | Sara Gandini, Laura Fancello, Pier Giuseppe Pelicci, Luca Mazzarella |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/7/1/183.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Oxidative Stress Response Gene P66SHC and the Tumor Suppressor Gene P53 Induce Mitochondrial Dna Damages
by: Mirella Trinei, et al.
Published: (2001-01-01) -
Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
by: Ming Zheng
Published: (2022-01-01) -
Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments
by: Amit Verma, et al.
Published: (2025-01-01) -
Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel
by: Seungkyu Choi, et al.
Published: (2016-09-01) -
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
by: Vivek Subbiah, et al.
Published: (2025-02-01)